You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Highly potent, competitive, preferential dopamine D3 receptor antagonist. Ki values are 0.52, 5, and 269 nM for human cloned D3, D2 and D4 receptors respectively. Centrally active upon systemic administration.
Sold with the permission of INSERM and BIOPROJET
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 365.47. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.74 mL||13.68 mL||27.36 mL|
|5 mM||0.55 mL||2.74 mL||5.47 mL|
|10 mM||0.27 mL||1.37 mL||2.74 mL|
|50 mM||0.05 mL||0.27 mL||0.55 mL|
References are publications that support the biological activity of the product.
Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel DA D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187 PMID: 9765337
Richtand et al (2000) The DA D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 867 239 PMID: 10837819
Sautel et al (1995) Nafadotride, a potent preferential DA D3 receptor antagonist, activates locomotion in rodents. J.Pharmacol.Exp.Ther. 275 1239 PMID: 8531087
If you know of a relevant reference for Nafadotride, please let us know.
View Related Products by Product Action
Keywords: Nafadotride, Nafadotride supplier, potent, preferential, D3, antagonists, Dopamine, Receptors, dopaminergic, 1347, Tocris Bioscience
2 Citations for Nafadotride
Citations are publications that use Tocris products. Selected citations for Nafadotride include:
Brewer et al (2014) DA D3 receptor dysfunction prevents anti-nociceptive effects of mor. in the spinal cord. Front Neural Circuits 8 62 PMID: 24966815
Clemens and Hochman (2004) Conversion of the modulatory actions of DA on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 11337 PMID: 15601940
Do you know of a great paper that uses Nafadotride from Tocris? Please let us know.
Reviews for Nafadotride
There are currently no reviews for this product. Be the first to review Nafadotride and earn rewards!
Have you used Nafadotride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.